By Counterforce Health Team in Adynovate (bdanocog alfa pegol) —

How to Get Adynovate (Antihemophilic Factor VIII) Covered by Aetna CVS Health in Michigan: Prior Authorization Forms, Appeals, and Documentation Requirements

Answer Box: Getting Adynovate Covered by Aetna CVS Health in Michigan

To get Adynovate (bdanocog alfa pegol) covered by Aetna CVS Health in Michigan:

  1. Submit prior authorization via CVS Caremark specialty fax at 1-888-267-3277 or call 1-855-240-0535
  2. Document medical necessity including hemophilia A severity (ICD-10: D66) and why extended half-life factor VIII is clinically required
  3. If denied, appeal within 180 days using Aetna's internal process, then file external review with Michigan DIFS within 127 days at 877-999-6442

Expected timeline: 30-45 days for standard PA decisions, 72 hours for expedited appeals in Michigan.

Table of Contents

  1. Who Should Use This Guide
  2. Member & Plan Basics
  3. Clinical Criteria for Adynovate Coverage
  4. Coding and Documentation Requirements
  5. Prior Authorization Submission Process
  6. CVS Specialty Pharmacy Enrollment
  7. After Submission: Tracking and Follow-Up
  8. Appeals Process in Michigan
  9. Common Denial Reasons and Solutions
  10. FAQ: Adynovate Coverage Questions

Who Should Use This Guide

This comprehensive checklist is designed for:

  • Patients with hemophilia A who need Adynovate (bdanocog alfa pegol) for prophylaxis or treatment
  • Hematologists and treating physicians submitting prior authorization requests
  • Care coordinators at hemophilia treatment centers navigating Aetna CVS Health coverage
  • Patients facing denials who need to understand Michigan's appeal rights

Expected outcome: With proper documentation and adherence to Aetna's clinical criteria, most medically necessary Adynovate requests are approved. If initially denied, Michigan's robust external review process provides an independent medical evaluation with binding decisions.

Member & Plan Basics

Coverage Verification Checklist

Before starting the prior authorization process, confirm:

  • ✅ Active Aetna CVS Health coverage (commercial, Medicare, or Medicaid)
  • ✅ Specialty pharmacy benefit through CVS Caremark
  • ✅ Deductible status and any copay requirements
  • ✅ In-network hematologist or treating physician
Tip: Call the member services number on your insurance card to verify specialty drug benefits and confirm whether Adynovate requires prior authorization under your specific plan.

Clinical Criteria for Adynovate Coverage

Medical Necessity Requirements

Primary Indication: Hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to prevent bleeding episodes
  • On-demand treatment of bleeding episodes

Step Therapy Considerations

Aetna typically requires step therapy for factor VIII products, meaning patients must try preferred products first unless:

  • Clinical contraindication to preferred agents
  • Documented treatment failure with preferred factor VIII products
  • Adverse reactions to standard half-life products
  • Lifestyle factors requiring extended half-life dosing

Dosing Guidelines for Approval

According to UnitedHealthcare and similar payer policies:

  • Prophylaxis: Maximum 50 IU/kg, no more than twice weekly
  • On-demand treatment: Based on bleeding severity and location
  • Individualized dosing based on patient's pharmacokinetic profile

Coding and Documentation Requirements

ICD-10 Codes

Condition ICD-10 Code Documentation Notes
Hemophilia A D66 Primary diagnosis; specify severity (severe <1%, moderate 1-5%, mild 5-40%)
Carrier status Z14.01 (asymptomatic) or Z14.02 (symptomatic) Secondary code if applicable

HCPCS Billing Codes

  • J7207: Injection, antihemophilic factor (recombinant), pegylated, (Adynovate), per IU
  • Bill based on actual units administered, not vials dispensed
  • Include NDC number and lot information in claims

Required Clinical Documentation

Essential elements for medical necessity:

  1. Hemophilia A diagnosis confirmation with factor VIII activity levels
  2. Bleeding history and frequency of episodes
  3. Prior factor VIII therapies tried and outcomes
  4. Rationale for extended half-life product (adherence, lifestyle, pharmacokinetics)
  5. Dosing plan with frequency and monitoring schedule

Prior Authorization Submission Process

Step-by-Step Submission Guide

1. Gather Required Documents

  • Completed Aetna prior authorization form
  • Medical necessity letter (see template below)
  • Recent clinic notes documenting hemophilia A severity
  • Laboratory results showing factor VIII levels
  • Documentation of prior therapies and outcomes

2. Submit via Preferred Method

3. Medical Necessity Letter Template

[Date]

Re: Prior Authorization Request for Adynovate® (bdanocog alfa pegol)
Patient: [Name, DOB, Member ID]
Diagnosis: Hemophilia A (ICD-10: D66)

Dear Medical Director:

I am requesting authorization for Adynovate for my patient with severe hemophilia A 
(factor VIII activity <1%). Clinical rationale includes:

• Patient requires prophylactic factor VIII replacement to prevent spontaneous bleeding
• Extended half-life product medically necessary due to [specific clinical reason]
• Proposed dosing: [X] IU/kg twice weekly, consistent with FDA labeling
• Prior therapies: [Document previous treatments and outcomes]

This request aligns with current MASAC guidelines and FDA-approved indications.

Sincerely,
[Provider name, NPI, contact information]

CVS Specialty Pharmacy Enrollment

Enrollment Process

Once prior authorization is approved:

1. Prescription Transfer

  • Hematologist sends prescription to CVS Specialty
  • Patient completes enrollment forms
  • Insurance verification and benefits investigation

2. Delivery Coordination

  • Home delivery or infusion center shipment
  • Cold-chain handling for factor concentrates
  • Patient education on storage and administration

3. Ongoing Support

  • Refill coordination and reminders
  • Insurance reauthorization management
  • 24/7 clinical support line
Note: CVS Specialty coordinates with Michigan hemophilia treatment centers to ensure seamless care transitions and proper handling of factor concentrates.

After Submission: Tracking and Follow-Up

Timeline Expectations

Review Type Standard Timeline Expedited Timeline
Initial PA decision 30-45 days 72 hours (with clinical urgency)
Internal appeal 30 days 72 hours
Michigan external review Up to 60 days 72 hours

Status Tracking

  • Confirmation number: Record reference number from submission
  • Follow-up schedule: Check status weekly if no response within expected timeframe
  • Documentation: Keep copies of all submissions and correspondence

Appeals Process in Michigan

Internal Appeals with Aetna CVS Health

Timeline: 180 days from denial notice to file internal appeal

Required documents:

  • Copy of denial letter
  • Additional clinical documentation
  • Updated medical necessity letter addressing denial reasons

Michigan External Review Process

If internal appeals are unsuccessful, Michigan residents have strong appeal rights:

Filing deadline: 127 days from final internal denial

How to file:

  • Online: Michigan DIFS External Review Request form
  • Phone: 877-999-6442
  • Fax/Mail: Submit paper forms to DIFS

Expedited review: Available if delay would harm patient health (requires physician letter)

Decision timeline:

  • Standard: Up to 60 days
  • Expedited: 72 hours
Important: Michigan's external review decisions are binding on insurers. If the Independent Review Organization approves coverage, Aetna must comply.

Common Denial Reasons and Solutions

Denial Reason Solution Strategy Required Documentation
"Not medically necessary" Provide detailed bleeding history and severity documentation Factor VIII levels, bleed logs, emergency department visits
"Preferred product not tried" Document step therapy completion or contraindications Prior authorization records, adverse event documentation
"Quantity exceeds plan limits" Justify individualized dosing based on patient factors Pharmacokinetic studies, weight-based calculations
"Experimental/investigational" Cite FDA approval and clinical guidelines FDA label, MASAC recommendations

FAQ: Adynovate Coverage Questions

Q: How long does Aetna CVS Health prior authorization take in Michigan? A: Standard decisions take 30-45 days. Expedited reviews for urgent medical needs are completed within 72 hours.

Q: What if Adynovate is non-formulary on my plan? A: You can request a formulary exception with documentation of medical necessity and why preferred alternatives aren't suitable.

Q: Can I request an expedited appeal if I'm having breakthrough bleeds? A: Yes. Michigan allows expedited external reviews when delays would harm patient health. Your physician must provide a supporting letter.

Q: Does step therapy apply if I've failed other factor VIII products outside Michigan? A: Prior therapy documentation from any location is typically accepted. Ensure complete records are submitted with your request.

Q: What's the cost of Adynovate if my appeal is denied? A: Adynovate costs approximately $2.57 per IU. Patient assistance programs through Takeda and hemophilia foundations may help with coverage gaps.

Q: Who can help me navigate the appeals process in Michigan? A: Contact Michigan DIFS at 877-999-6442, your hemophilia treatment center social worker, or organizations like Counterforce Health that specialize in insurance appeals for specialty medications.

From Our Advocates

"We've seen many Adynovate denials overturned when providers clearly document why extended half-life factor VIII is medically necessary for the individual patient. The key is connecting clinical factors like adherence challenges, lifestyle needs, or pharmacokinetic differences to the specific benefits of Adynovate's dosing schedule. Michigan's external review process is particularly patient-friendly—don't give up after an internal denial."

Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into successful appeals by creating targeted, evidence-backed responses. Our platform analyzes denial letters and plan policies to draft point-by-point rebuttals that align with payer requirements, pulling the right clinical evidence and procedural details to maximize approval rates. For complex cases like factor VIII coverage, having expert support can make the difference between a successful appeal and ongoing coverage barriers.

Printable Checklist: Pre-Submission Requirements

Before submitting your Adynovate prior authorization:

  • Patient information complete (name, DOB, member ID, contact)
  • Diagnosis confirmed (Hemophilia A with severity level documented)
  • ICD-10 code included (D66 for hemophilia A)
  • Prior therapies documented (what was tried, outcomes, reasons for change)
  • Dosing plan specified (frequency, units, monitoring schedule)
  • Medical necessity letter addresses clinical rationale for Adynovate specifically
  • Supporting documents attached (labs, clinic notes, bleed logs)
  • Correct submission method (fax 1-888-267-3277 or call 1-855-240-0535)
  • Confirmation number recorded for tracking purposes
  • Follow-up scheduled if no response within 30 days

Sources & Further Reading

Disclaimer: This information is for educational purposes and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan for specific coverage decisions. Coverage policies and appeal processes may change; verify current requirements with official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.